A phase II study of thalidomide in advanced metastatic renal cell carcinoma.
- 1 January 2002
- journal article
- clinical trial
- Published by Springer Nature in Investigational New Drugs
- Vol. 20 (4) , 389-393
- https://doi.org/10.1023/a:1020669705369
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Thalidomide: current and potential clinical applicationsPublished by Elsevier ,2004
- The treatment of advanced renal cell cancer with high-dose oral thalidomideBritish Journal of Cancer, 2001
- A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myelomaCancer Treatment Reviews, 2000
- Activity of Thalidomide in AIDS-Related Kaposi’s SarcomaJournal of Clinical Oncology, 2000
- Antitumor Activity of Thalidomide in Refractory Multiple MyelomaNew England Journal of Medicine, 1999
- Structure of the VHL-ElonginC-ElonginB Complex: Implications for VHL Tumor Suppressor FunctionScience, 1999
- S.T.E.P.S.™: A comprehensive program for controlling and monitoring access to thalidomideClinical Therapeutics, 1999
- A sensitive fluorometric enzyme-linked immunosorbent assay that measures vascular endothelial growth factor165 in human plasmaJournal of Immunological Methods, 1998
- Thalidomide is an inhibitor of angiogenesis.Proceedings of the National Academy of Sciences, 1994
- The Saga of ThalidomideNew England Journal of Medicine, 1962